Janus Henderson Group
AVIR icon

Janus Henderson Group’s Atea Pharmaceuticals AVIR Stock Holding History

Janus Henderson Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-35,909
Closed -$120K – 2601
2023
Q1 		$120K Buy
35,909
+17,769
+98% +$72.1K ﹤0.01% 2597
2022
Q4 		$87.2K Buy
18,140
+1
+0% +$5 ﹤0.01% 2357
2022
Q3 		$104K Buy
+18,139
New +$139K ﹤0.01% 2042

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group's AVIR Position: Q2 2023 in Review

Janus Henderson Group sold out of Atea Pharmaceuticals (AVIR) in Q2 2023, closing a stake of 35,909 shares — an estimated $120K sold.

Janus Henderson Group first reported a position in AVIR in Q3 2022 and held it in 3 quarters. The position peaked at $120K in Q1 2023. 133 funds tracked by Wall St. Rank hold AVIR as of Q2 2023.

  • Janus Henderson Group reported no remaining Atea Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Janus Henderson Group sold 35,909 Atea Pharmaceuticals shares in Q2 2023, an estimated $120K.
  • Janus Henderson Group first reported a position in Atea Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Janus Henderson Group's Atea Pharmaceuticals position peaked at $120K in Q1 2023.
  • 133 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2023.

Based on Janus Henderson Group's 13F filing for Q2 2023, filed 14 Aug 2023.